Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A



Status:Completed
Conditions:Shingles, Infectious Disease
Therapuetic Areas:Dermatology / Plastic Surgery, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - Any
Updated:12/14/2017
Start Date:July 14, 2009
End Date:March 21, 2012

Use our guide to learn which trials are right for you!

Safety and Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

The purpose of this observer-blind study is to evaluate the safety and immunogenicity of
GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when
administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.

The Protocol Posting has been updated following Protocol amendment 2, Sep 2009. The sections
impacted are: eligibility criteria.

Inclusion Criteria:

- Subjects who the investigator believes that they can and will comply with the
requirements of the protocol;

- Male and female subjects at least 18 years old at the time of vaccination;

- Serological evidence of prior VZV infection for all subjects born in 1980 or later and
for subjects born outside the US before 1980 in a tropical or sub-tropical region. No
testing for serological evidence of prior VZV infection is required for US subjects
born before 1980;

- Has undergone autologous HCT within the past 50-70 days for treatment of Hodgkin
lymphoma, non-Hodgkin lymphoma (T or B cell), myeloma or acute myeloid leukemia, and
there are no plans for additional HCTs

- Written informed consent obtained from the subject;

- If the subject is female, she must be of non-childbearing potential or if she is of
childbearing potential, she must practice adequate contraception for 30 days prior to
vaccination, have a negative pregnancy test and continue such precautions for 2 months
after completion of the vaccination series.

Exclusion Criteria:

- Use of any investigational non-registered product other than the study vaccine(s)
within 30 days preceding the first dose of study vaccine, or planned use during the
study period;

- Administration or planned administration of a vaccine that is not part of the study
protocol since transplantation. However licensed non-replicating vaccines (i.e.
inactivated and subunit vaccines, including inactivated and subunit influenza
vaccines, with or without adjuvant) may be administered up to 8 days prior to dose 1;

- Administration of immunoglobulins since transplantation;

- Previous vaccination against varicella or HZ;

- History of HZ within the previous 12 months;

- Known exposure to VZV since transplantation;

- Evidence of active infection at the time of enrollment including a temperature of ≥
37.5° C or any serious HCT-related complication;

- History of allergic disease or reactions likely to be exacerbated by any component of
the vaccine;

- Hypersensitivity or intolerance to acyclovir or valacyclovir;

- Pregnant or lactating female.
We found this trial at
11
sites
Duarte, California 91010
?
mi
from
Duarte, CA
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cleveland, Ohio 44195
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Frisco, California 94115
?
mi
from
Frisco, CA
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Minnesota, Minnesota 55455
?
mi
from
Minnesota, MN
Click here to add this to my saved trials
New York, New York 10032
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials